NCT03044873

Effect of BMS-986165 on the Pharmacokinetics of Rosuvastatin

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Accepted

Summary

The study is to assess the effect of coadministration of multiple doses of BMS-986165 on the systemic exposure of rosuvastatin in healthy participants.

Conditions

• Autoimmune Diseases
• Inflammatory Diseases

Interventions

Type	Name	Description
DRUG	BMS-986165	Rosuvastatin on Day 1. BMS 986165 on Days 5-8 and Days 10-12. On Day 9, BMS 986165 coadministered with an oral dose of rosuvastatin.
DRUG	Rosuvastatin	Rosuvastatin on Day 1. BMS 986165 on Days 5-8 and Days 10-12. On Day 9, BMS 986165 coadministered with an oral dose of rosuvastatin.

Timeline

• Start date: 2017-02-02
• Primary completion: 2017-03-14
• Completion: 2017-03-27
• First posted: 2017-02-07
• Last updated: 2017-04-17

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study